Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07795086 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype

Name: Comparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype — clinical trial record (NCT07795086)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: COPD

StatusNot Yet Recruiting

PhasePhase 4

SponsorSidra Aziz

Started2027-02

View on ClinicalTrials.gov ↗

"The study is a randomized controlled trial comparing roflumilast and azithromycin as add-on therapies in 70 patients with severe chronic obstructive pulmonary disease (COPD ) and frequent exacerbations. Participants will receive one of the two treatments for six months while continuing standard inhaled therapy. The study aims to determine which drug is more effective in reducing exacerbations and improving clinical outcomes such as forced expiratory volume in one second( FEV1) and modified medical research council ( mMRC)dyspnea scale , hospitalization, adherence, and safety, thereby providing evidence to guide chronic obstructive pulmonary disease management in our local population."

Trial Details

NCT Number	NCT07795086
Lead Sponsor	Sidra Aziz Collaborators: Sheikh Zayed Medical College
Conditions	Chronic Obstructive Pulmonary Disease With Exacerbation
Enrollment	70 participants
Start Date	2027-02
Primary Completion	2027-02 (estimated)
Study Completion	2027-02 (estimated)
Updated on ClinicalTrials.gov	2026-08-31